Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of GLP-1 analogs and derivatives administered peripherally in regulation of obesity

A technology of GLP-1 and analogs, applied in the direction of medical preparations containing active ingredients, drug combinations, chemical instruments and methods, etc., can solve the impractical problems of obese patients

Inactive Publication Date: 2000-01-26
ELI LILLY & CO
View PDF15 Cites 14 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

These discussions do not support the use of GLP-1 as a weight loss composition (agent) because administration by a central route such as the ICV route is impractical for treating obese patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0203] 4 patients with non-insulin-dependent diabetes mellitus (NIDDM) (3 males, 1 female; age: 60.2±1.8 years; initial BMI: 33.5±1.4kg / m 2 ; starting body weight: 97.5±6.5kg; starting waist / hip ratio: 0.946±0.036; starting HbAlc: 7.1±0.3%; fasting blood glucose: 7.2±1.1mM) receiving continuous GLP-1 (7-36) Subcutaneous infusion of amide for 4 weeks. The preparation method of GLP-1 solution is as follows: combine 100nmol GLP-1(7-36) amide and 0.025mL human albumin solution (20%), then adjust the pH to 4 with 5 moles of acetic acid, and finally add physiological saline to 1mL. GLP-1 solution was administered at a dose rate of 1.2 pmol / kg / min. The volume infusion rate of the Minimed pump (Minimed Europe, Paris) used for GLP-1 administration was 0.05-0.07 mL / h. The site for subcutaneous administration is the abdomen.

[0204] This GLP-1 treatment was compared with two weeks of intensive insulin treatment before and after GLP-1 infusion. During insulin therapy, inject insulin ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to the use of glucagon-like peptides such as GLP-1, GLP-1 analogs or GLP-1 derivatives in weight reduction methods and compositions.

Description

Background of the invention [0001] The present invention relates to the use of glucagon-like peptide-1 (GLP-1), GLP-1 analogs and derivatives in methods and compositions, especially pharmaceutical formulations, to aid in weight loss. [0002] Obesity, especially upper body obesity, is the most common nutritional disorder among the world's overnourished populations. Numerous studies have confirmed that weight loss can greatly reduce the risk of chronic diseases such as diabetes, hypertension, hyperlipidemia, coronary heart disease and musculoskeletal disease. For example, various markers of obesity, including body weight alone, waist / hip ratio, and mesenteric fat storage, are strongly associated with non-insulin-dependent diabetes mellitus (NIDDM), also known as type II diabetes. According to the American Diabetes Association (1995), approximately 80% of NIDDM patients are overweight. Weight loss is a specific goal of the treatment of many chronic diseases including NIDDM. ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/00A61K38/26C07K14/605
CPCY10S514/866A61K38/26Y10S514/909C07K14/605A61P3/04
Inventor R·D·蒂马赤S·埃芬迪克
Owner ELI LILLY & CO
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com